For the quarter ending 2026-03-31, EDIT had -$22,997K decrease in cash & cash equivalents over the period. -$23,153K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -24,982 | -5,620 | -25,117 | -129,323 |
| Loss on disposal of fixed assets | - | 0 | 0 | -2,193 |
| Stock-based compensation expense | 2,102 | 2,129 | 2,228 | 5,643 |
| Depreciation | 483 | 805 | 721 | 3,751 |
| Net amortization of premiums and discounts on marketable securities | 0 | 0 | 62 | 840 |
| Other non-cash items | -111 | 59 | 0 | 390 |
| Impairment of held for sale assets | 0 | 34 | 0 | 3,724 |
| Interest related to sale of future revenues | 1,072 | -464 | 2,399 | 4,236 |
| Accounts receivable | -12,584 | 7,046 | 7,542 | -15,678 |
| Prepaid expenses and other current assets | -248 | -887 | -593 | 418 |
| Right-of-use assets | -709 | -1,462 | -1,428 | -8,694 |
| Other non-current assets | 0 | -14 | -1 | -1,025 |
| Accounts payable | 1,727 | -558 | -3,561 | 1,231 |
| Accrued expenses | -11,362 | -14,912 | -543 | 2,271 |
| Accrued interest on sale of future revenues | -5,000 | 0 | 0 | -2,128 |
| Deferred revenue | 0 | -9,695 | 0 | -6,221 |
| Operating lease liabilities | -805 | -1,550 | -1,483 | -9,048 |
| Other non-current liabilities | 52 | -1,814 | 95 | 1,911 |
| Net cash used in operating activities | -23,061 | -36,387 | -30,843 | -98,011 |
| Purchases of property and equipment | 92 | 60 | 433 | 114 |
| Proceeds from the sale of equipment | 156 | 118 | 0 | 151 |
| Purchases of marketable securities | - | 0 | 0 | 0 |
| Proceeds from maturities of marketable securities | 0 | 0 | 40,006 | 99,000 |
| Net cash provided by (used in) investing activities | 64 | 58 | 39,573 | 99,037 |
| Repayment on sale of future revenues | 0 | 0 | 0 | 2,872 |
| Issuance of common stock under benefit plans | - | 196 | 0 | 228 |
| Proceeds from sale of future revenues, net | - | 0 | - | - |
| Proceeds from exercise of stock options | - | 49 | 21 | 0 |
| Proceeds from issuance of common stock from at-the-market equity offering | 0 | 17,081 | 17,148 | 8,619 |
| Net cash used in financing activities | 0 | 17,326 | 17,169 | 5,975 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | -22,997 | -19,003 | 25,899 | 7,001 |
| Cash, cash equivalents, and restricted cash, beginning of period | 149,315 | 168,318 | 135,418 | - |
| Cash, cash equivalents, and restricted cash, end of period | 126,318 | 149,315 | 168,318 | - |
Editas Medicine, Inc. (EDIT)
Editas Medicine, Inc. (EDIT)